Caremark Rx Scheduled to Speak at the Raymond James & Associates Conference March 6, 2001.
BIRMINGHAM, Ala., Feb. 27 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX) today announced its intention to present at the upcoming Raymond James & Associates 2001 Institutional Investors Conference. The presentation is scheduled for Tuesday, March 6, 2001 at The Hyatt Regency Grand Cypress in Orlando, Florida. The...

Caremark Rx Scheduled to Speak at The Robinson-Humphrey 30th Annual Institutional Conference April 9, 2001.
BIRMINGHAM, Ala., April 3 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX) today announced its intention to present at the upcoming Robinson-Humphrey 30th Annual Institutional Conference. The presentation is scheduled for Monday, April 9, 2001 at The Ritz-Carlton, Buckhead in Atlanta. The presentation will also be broadcast live...

Genzyme General Acquires Lisfarma.
Acquisition Will Accelerate Launch of Renagel(R) in Brazil CAMBRIDGE, Mass., April 2 /PRNewswire/ -- Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has acquired Lisfarma Importacao, Exportacao e Comercio Ltda., a privately held pharmaceutical and medical company based in Sao...

TKT Completes $100 Million Public Offering of Common Stock.
CAMBRIDGE, Mass., July 2 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced the completion of its follow-on public offering, raising a total of $100,177,500. A total of 3,515,000 shares were sold at $28.50 per share, including 415,000 shares to cover overallotments. SG Cowen Securities Corporation acted...

TKT Reports First Quarter 2001 Financial Results.
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) reported today financial results for the quarter ended March 31, 2001. For the first quarter of 2001, the Company had a net loss of $14,032,000, or $0.62 per share, compared to a net loss of $13,099,000,...

Dr. Heather Munroe-Blum Joins Visible Genetics' Board.
TORONTO, July 24 /PRNewswire/ -- Visible Genetics Inc. (VGI, Nasdaq: VGIN) today announced that Heather Munroe-Blum, Ph.D., who has been Vice-President, Research & International Relations at the University of Toronto since 1994, has joined the Visible Genetics' Board of Directors, replacing Michael Cardiff who stepped down from...

TKT Announces $42 Million Public Offering of Common Stock.
CAMBRIDGE, Mass. -- Transkaryotic Therapies, Inc. today announced the public offering of 1,000,000 shares of its common stock at a purchase price of $42.00 per share. All of the shares were offered by TKT. The Company intends to use the net proceeds from the sale of the common stock...

Vysis Elects Richard A. Lerner, M.D. as Director; Appointment Increases Board To Seven.
DOWNERS GROVE, Ill., Feb. 27 /PRNewswire/ -- Vysis, Inc. (Nasdaq: VYSI), announced today that its Board of Directors has elected Richard A. Lerner, M.D., President of The Scripps Research Institute., as a Director effective immediately. Dr. Lerner, 62, has been President of The Scripps Research...

Caremark Rx Scheduled to Speak at the Goldman, Sachs & Co. 22nd Annual Healthcare Conference June 14, 2001.
BIRMINGHAM, Ala., June 7 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX), today announced its intention to present at the upcoming 22nd Annual Healthcare Conference hosted by Goldman, Sachs & Co. The presentation is scheduled for Thursday, June 14, 2001, at The Ritz-Carlton Laguna Niguel, Dana Point, Calif....

Vysis Grants License to bioMerieux, Inc. Under Its Collins Patent.
Technology Improves Sensitivity of DNA Probe Technology Using Amplification DOWNERS GROVE, Ill., July 10 /PRNewswire/ -- Vysis, Inc. (Nasdaq: VYSI), a developer and marketer of DNA-based clinical products providing information for genomic disease management, announced today that it has granted a nonexclusive license to bioMerieux,...